GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Net Income (Continuing Operations)

Oncodesign Precision Medicine (XPAR:ALOPM) Net Income (Continuing Operations) : €-6.86 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Oncodesign Precision Medicine's Net Income (Continuing Operations) for the six months ended in Dec. 2024 was €-3.46 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was €-6.86 Mil.

Oncodesign Precision Medicine Net Income (Continuing Operations) Historical Data

The historical data trend for Oncodesign Precision Medicine's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Net Income (Continuing Operations) Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
-4.71 -2.94 -0.23 -8.10 -6.86

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income (Continuing Operations) Get a 7-Day Free Trial 3.03 -3.94 -4.15 -3.40 -3.46

Oncodesign Precision Medicine Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine  (XPAR:ALOPM) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Oncodesign Precision Medicine Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Net Income (Continuing Operations)
Comparable Companies
XPAR:ALTAO XPAR:ALTME XPAR:ALTHX XPAR:ALINT XPAR:ALVIO XPAR:ALBPS XPAR:ALPAT XPAR:ALNFL XPAR:ALNEV XPAR:ALCOX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ZR8:Germany
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines